회원가입 | 연락처 | 사이트맵 | English

      회사소개 | 리포트 | 커스텀 리서치 | 고객지원


로그인

카테고리

유/무선통신

전기/전자

디지털기기/미디어/방송

Information Technology

에너지

생명공학

화학/신소재

자동차

환경

일반소비재

마케팅/광고

금융

건설

교통/운송

소비자조사

방위/항공/우주

식음료

중공업

교육

기계

무역

스포츠/레저

해운/조선

패션

정부/정책

공예/귀금속

컴퍼니 프로파일

기타산업

 
현재위치 : HOME > 리포트 > 생명공학 > 제약
Investigation Report on China Alendronate Sodium Market, 2010-2019
발행사 China Research and Intelligence

발행일 2015-06
분량 30 pages
서비스형태 Report
판매가격

인쇄하기

Description

China has become the country with the largest number of people suffering from osteoporosis which is the most severe disease second to cardiovascular diseases. A nationwide large-scale epidemiological survey has also shown that the incidence of osteoporosis in China is 12.4% and that this figure among elders is over 50%, among which nearly 33% suffer from fracture. It is estimated that the number of osteoporosis patients and patients with low bone mass will rise to 280 million by 2020. Hence osteoporosis drugs’ promising future.
Alendronate sodium is one of the osteoporosis drugs with the longest history of application. And it is the first diphosphonate that got FDA’s approval to be used for the treatment of postmenopausal osteoporosis and the first drug approved by FDA to treat osteoporosis in men.
By various mechanisms of action, alendronate sodium can enhance bone strength, alleviate and prevent osteoporosis, effectively reduce the risk of fracture in centrum, hip bone and other parts. It is also the only drug that can effectively reduce the risk in various parts of the body especially in hip.
Alendronate sodium develops fast after entering China, annual sales value rising from less than CNY 30 million in 2005 to CNY 121 million in 2014 and CAGR during this period reaching 18.14%. Merck Sharp & Dohme (Italy), CSPC Ouyi Pharmaceutical Co., Ltd, Beijing Wansheng Pharmaceutical Co., Ltd, Haini Pharmaceutical Co., Ltd and Chengdu Tiantaishan Pharmaceutical Co., Ltd occupy the majority of market share, among which Merck Sharp & Dohme (Italy) has the largest market share of nearly 90% for sales value in 2014.
The ageing population in China keeps growing, people aged 60 and above amounting to 212.42 million and occupying 15.5% of the total population while people aged 65 and above amounting to 137.55 million and occupying 10.1% of the total population by the end of 2014. With the ageing population, the incidence and number of cases of osteoporosis will continue to grow. Therefore the market size of alendronate sodium is expected to keep expanding in the next few years in China.

Readers can get at least the following information from this report:

-market size of alendronate sodium in China
-competitive landscape of alendronate sodium in Chinese market
-price of alendronate sodium made by different enterprises in China
-market outlook of alendronate sodium in China

The author suggests the following groups of people purchase this report:

-manufacturers of osteoporosis drugs
-investors/ research institutions interested in Chinese medicine market
-any interest in the Chinese medicine market, please contact CRI for customized survey service


회사소개 | 개인정보보호정책 | 이용약관 | 배송/결제안내 | 이용안내

서울시 강남구 논현동 210-1 삼원빌딩 | 회사명 : (주)엘앤에치
대표전화 : 02-554-0001 / 팩스 : 02-3444-5501 / 이메일 : sales@landh.co.kr
Copyright ⓒ 2008 LNH, Inc. All rights reserved.